Romeu Belkis, González Elizabeth, Zayas Caridad, Del Campo Judith, Acevedo Reinaldo, Cuello Maribel, Valdes Yolanda, Balboa Julio, Cabrera Osmir, Lastre Miriam, Pérez Oliver
Immunology Department, Havana, Cuba.
Scand J Infect Dis. 2011 Oct;43(10):809-13. doi: 10.3109/00365548.2011.586648. Epub 2011 Jun 15.
Increasing emphasis is being placed on the mucosal administration of vaccines in order to stimulate mucosal as well as systemic responses. Findings from our group suggest that proteoliposome-derived cochleate (AFCo1) acts as a potent mucosal adjuvant. As an alternative to chemical conjugation, the current study aimed to determine the benefit of using AFCo1 to improve the mucosal and systemic immune responses to capsular polysaccharide of Neisseria meningitidis serogroup C (PsC), a model of a thymus-independent (TI) antigen. Therefore, intranasal (i.n.) immunization of 3 doses 1 week apart with AFCo1 plus PsC in mice was conducted. Highly specific anti-PsC IgA responses and an anti-PsC IgG response were obtained. The subclass pattern induced against PsC was similar to that induced with the meningococcal vaccine. In summary, AFCo1 as nasal adjuvant was demonstrated to be capable of eliciting mucosal and systemic specific responses against a TI antigen.
为了刺激黏膜和全身反应，疫苗的黏膜给药正受到越来越多的重视。我们团队的研究结果表明，蛋白脂质体衍生的螺旋体（AFCo1）可作为一种有效的黏膜佐剂。作为化学偶联的替代方法，本研究旨在确定使用AFCo1改善对C群脑膜炎奈瑟菌荚膜多糖（PsC）（一种非胸腺依赖性（TI）抗原模型）的黏膜和全身免疫反应的益处。因此，在小鼠中进行了每隔1周3次鼻内（i.n.）免疫AFCo1加PsC的实验。获得了高度特异性的抗PsC IgA反应和抗PsC IgG反应。诱导产生的针对PsC的亚类模式与脑膜炎球菌疫苗诱导的模式相似。总之，AFCo1作为鼻用佐剂被证明能够引发针对TI抗原的黏膜和全身特异性反应。
